 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Genta Incorporated
 |
Genta Incorporated |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Genta names Alfred Fernandez CFO Jul 26 2001 06:14 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Genta plays rough with cancer. The firm develops oligonucleotide cancer drugs that regulate the production of disease-related proteins at the genetic level. Its lead drug candidate is Genasense, an antisense compound that disrupts the production of proteins by the bcl-2 gene, thought to be responsible for such cancers as lymphoma, leukemia, and melanoma. The FDA has given Genasense orphan drug status as a treatment for melanoma. Genta also develops treatments to prevent bone resorption; one product, Ganite, has received FDA approval. Its Genta Jago Technologies joint venture with SkyePharma develops generic controlled-release drugs. Dr. Lindsay Rosenwald of Paramount Capital Asset Management owns 80% of Genta.
COMPETITION |
 |
Chiron Corporation (CHIR)
Isis Pharmaceuticals, Inc. (ISIP)
NeoPharm, Inc. (NEOL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: 0.0%
Employees: 21
Revenue per employee: $4,761.90
KEY PEOPLE |
 |
Raymond P. Warrell
CEO
Alfred J. Fernandez
CFO
CONTACT INFO |
 |
Two Oak Way
Berkeley Heights, NJ 07922
US
Phone: 908-286-9800
Fax: 908-464-1701
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |